Document Detail


Dronedarone: a new antiarrhythmic agent for the treatment of atrial fibrillation.
MedLine Citation:
PMID:  19690474     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In the armamentarium for rhythm control, amiodarone has been a mainstay of therapy for the management of atrial fibrillation (AF). Although amiodarone has shown to be effective in maintaining sinus rhythm, it has many extracardiac adverse effects. Dronedarone, a benzofuran amiodarone derivative, is structurally modified to reduce toxicities often associated with chronic amiodarone therapy. With the addition of a methylsulfonyl group, dronedarone is less lipophilic, has lower tissue accumulation, and a much shorter serum half-life of 24 hours compared with amiodarone. Dronedarone is also designed without the iodine moieties that are responsible for thyroid dysfunctions associated with amiodarone. Similar to amiodarone, dronedarone exhibits electrophysiologic characteristics of all 4 Vaughan Williams classifications. Phase III clinical trials have shown dronedarone to be effective at reducing ventricular rate, reducing recurrence of AF, and reducing cardiovascular morbidity and mortality in patients with AF or atrial flutter (AFL). However, dronedarone was associated with increased mortality in one study that included patients with severe heart failure (HL) and left ventricular dysfunction. Overall, dronedarone appears to be well tolerated. The most common side effects are gastrointestinal in nature and include nausea, vomiting, and diarrhea. Because of its more favorable adverse effect profile, dronedarone is likely to be a useful addition to the therapeutic management of AF. However, further comparative studies with amiodarone are needed to define dronedarone's place in therapy more clearly.
Authors:
Danielle Garcia; Angela Cheng-Lai
Related Documents :
11174354 - Pharmacologic management of atrial fibrillation: current therapeutic strategies.
18379654 - Predictors of postoperative atrial fibrillation after coronary artery bypass graft surg...
15286934 - Different features of ventricular arrhythmias and the rr-interval dynamics in atrial fi...
10210494 - Right atrial focal atrial fibrillation: electrophysiologic characteristics and radiofre...
24134954 - Chronic akt1 deficiency attenuates adverse remodeling and enhances angiogenesis after m...
11889304 - Predictors and impact of atrial fibrillation after isolated coronary artery bypass graf...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Cardiology in review     Volume:  17     ISSN:  1538-4683     ISO Abbreviation:  Cardiol Rev     Publication Date:    2009 Sep-Oct
Date Detail:
Created Date:  2009-08-19     Completed Date:  2009-10-26     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9304686     Medline TA:  Cardiol Rev     Country:  United States    
Other Details:
Languages:  eng     Pagination:  230-4     Citation Subset:  IM    
Affiliation:
Department of Pharmacy, Montefiore Medical Center, Bronx, NY, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amiodarone / adverse effects,  analogs & derivatives*,  pharmacokinetics,  therapeutic use
Anti-Arrhythmia Agents / adverse effects,  pharmacokinetics,  therapeutic use*
Atrial Fibrillation / drug therapy*
Diarrhea / chemically induced
Humans
Nausea / chemically induced
Chemical
Reg. No./Substance:
0/Anti-Arrhythmia Agents; 0/dronedarone; 1951-25-3/Amiodarone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Lipoprotein-associated phospholipase A2: an independent predictor of cardiovascular risk and a novel...
Next Document:  Should saphenous vein grafts be the conduits of last resort for coronary artery bypass surgery?